tbuckley/cabot-search huggingface dataset:
Fluoxetine and Repetitive Behaviors in Children and Adolescents With Autism Spectrum Disorder
Authors: Bryan H. King
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P1.04-32 Ki67+PD-1+ Central Memory CD8 T-Cell Frequencies Predict Response Upon Nivolumab+Ipilimumab in Malignant Pleural Mesothelioma
Authors: J. Mankor, M. Disselhorst, M. Poncin, H. Vroman, P. Baas, J. Aerts
Journal: Journal of Thoracic Oncology (2019)
OA03.01 A Non-Randomized, Open-Label, Prospective, Multicenter Study of Apatinib as Second-Line and Later-Line Therapy in Patients with ES-SCLC
Authors: D. Hua, Q. Liu, J. Xu, Y. Xu, M. Chen, L. Deng, J. Wu, T. Zhou, L. Zhang, J. Tan, X. Pu, Y. Shang, J. Hua, Y. Li, W. Cai, Y. Gu, X. Peng
Journal: Journal of Thoracic Oncology (2019)
P1.16-43 Prevalence of Clinical and Sub-Clinical Malnutrition in Advanced Non-Small-Cell Lung Cancer Patients and Association with Outcome
Authors: I. Trestini, I. Sperduti, M. Sposito, D. Kadrija, A. Drudi, D. Tregnago, A. Avancini, V.P. Di Noia, A. Gkountakos, E. D'Argento, L. Carbognin, M. Lanza, A. Santo, M. D'Onofrio, G. Tortora, E. Bria, M. Milella, S. Pilotto
Journal: Journal of Thoracic Oncology (2019)
P1.17-03 Inter-Fraction Variability of 18-FDG PET During Lung SBRT and the Effect of Systemic and Immunotherapy: Results of a Prospective Pilot Study
Authors: S. Tian, J. Switchenko, I. Sethi, X. Yang, A. Da Silva, T. Owonikoko, D. Schuster, W. Curran, K. Higgins
Journal: Journal of Thoracic Oncology (2019)
FDG PET/CT of Cervical Gout With Spinal Cord Compression
Authors: Berivan Emsen, Alexandre Fitoussi, Julia Chalaye, Clovis Adam, Emmanuel Itti
Journal: Clinical Nuclear Medicine (2019)

Abstract We report FDG PET/CT images of a 63-year-old woman referred for characterization of osteolytic lesions of the cervical spine. This patient with chronic renal failure had a history of follicular thyroid carcinoma with undifferentiated cells, treated by a total thyroidectomy, completed by radioactive iodine in 2017. Because of cancer history, a FDG PET/CT was performed and showed multiple moderately hypermetabolic osteolytic lesions of the spine from C3 to T1, with joint erosion on CT. A laminectomy was performed for cervical spinal cord decompression and revealed a gouty tophus.
P1.03-36 Cell-Free DNA Levels in Liquid Biopsy from Patients with Non-Small Cell Lung Cancer and Association with Clinical Parameters and Disease Outcome
Authors: N. Zampieri Pontes, F. Ferreira Da Silva, Y. Camargo Rodrigues, P. De Marchi, A. Lengert, R. Reis, L. Leal
Journal: Journal of Thoracic Oncology (2019)
P1.04-41 Immunotherapy Concomitant to Radiotherapy: A Multicentric Retrospective Study on 179 Patients with Advanced Non-Small Cell Lung Cancer
Authors: A. Bruni, P. Ciammella, L. Falcinelli, C. Greco, N. Giaj Levra, D. Franceschini, M. Perna, L. Frassinelli, A. Taddeo, V. Maragna, M.L. Bonu', S. Marani, R. Rossi, M. Taraborrelli, E. D'Angelo, F. Bertolini, P. Borghetti, V. Scotti
Journal: Journal of Thoracic Oncology (2019)
EP1.11-06 Design and Implementation of an Integrated Lung Cancer Prevention and Screening Program Using a Mobile CT in Brazil
Authors: R. Chiarantano, F. Vazquez, R. Haikel Junior, L. Ferreira, M. Da Costa, L. Leal, P. De Marchi, M.C. Meinberg, A. Franco, L. Almeida, E. Mauad, R. Reis
Journal: Journal of Thoracic Oncology (2019)
P2.18-12 Prognostic Nutrition Index Affects Prognosis of Trimodality Therapy for Locally Advanced Lung Cancer with High T Factor
Authors: J. Soh, K. Suzawa, K. Shien, S. Otani, H. Yamamoto, M. Okazaki, S. Sugimoto, M. Yamane, T. Oto, K. Kiura, S. Toyooka
Journal: Journal of Thoracic Oncology (2019)
Career Development of Young Physician–Scientists in the Cardiovascular Sciences
Authors: Sachin Agarwal, Edda Spiekerkoetter, Eric D. Austin, Vinicio de Jesus Perez, Cameron Dezfulian, Bradley A. Maron, John J. Ryan, Monique A. Starks, Paul B. Yu, Sebastien Bonnet, Sarah M. Perman
Journal: Circulation Research (2018)
P1.14-18 ALK Inhibitor Sequencing and Outcomes Among ALK-Positive (ALK+) NSCLC Patients in the US Community Oncology Setting
Authors: D. Waterhouse, J. Espirito, M. Chioda, B. Baidoo, J. Mardekian, N. Robert, E. Masters
Journal: Journal of Thoracic Oncology (2019)
MA06.07 E1505: Adjuvant Chemotherapy +/- Bevacizumab for Early Stage NSCLC: Updated Chemotherapy Subset Analysis
Authors: H. Wakelee, S. Dahlberg, S. Keller, W. Tester, S. Aisner, J. Rothman, J. Patel, R. Delaune, S. Mcdermott, A. Shafqat, R. Perez-Soler, A. Chapman, S. Kasbari, A. Traynor, T. Evans, L. Horn, S. Graziano, D. Gandara, A. Adjei, C. Butts, N. Leighl, S. Ramalingam, J. Schiller
Journal: Journal of Thoracic Oncology (2019)
EP1.16-05 Real World Outcomes of Advanced NSCLC Patients with Liver Metastases
Authors: J. Law, C. Pettengell, L. Chen, L. Le, M. Sung, S. Aviv, S. Lau, A. Sacher, D. Merritt, P. Demarco, N. Leighl
Journal: Journal of Thoracic Oncology (2019)
P2.18-16 VATS Lobectomy and Chest Wall Resection for NSCLC
Authors: H. Melek, B. Özkan, H. Kara, E. Kaba, A. Bayram, M. Ülker, E. Erşen, A. Turna, A. Toker, C. Gebitekin
Journal: Journal of Thoracic Oncology (2019)
P2.14-10 Identification of Frequent, Activating HER2 Mutations and HER2 Inhibitor Response and Resistance in Canine Lung Cancer
Authors: G. Lorch, V. Zismann, N. Perdigones, T. Contente-Cuomo, A. Nazareno, S. Facista, S. Wong, W. Liang, J. Amann, S. Sinicropi-Yao, M. Koenig, K. La Perle, A. Lalani, I. Diala, L. Eli, T. Whitsett, J. Trent, M. Murtaza, D. Carbone, W. Hendricks
Journal: Journal of Thoracic Oncology (2019)
P1.17-27 Stereotactic Radiotherapy for Primary Lung Tumors: The Influence of Size
Authors: I. Rodrigues, T. Figueiredo, J. Gagean, C. Ferreira, A. Laranja, T. Ramos, S. Conde, D. Moreira, L. Carvalho, J. Cardia
Journal: Journal of Thoracic Oncology (2019)
P1.10-05 Tobacco Retail Availability and Tobacco Cessation Among Lung Cancer Survivors
Authors: L. Eng, J. Su, K. Hueniken, M.C. Brown, A. Hope, A. Bezjak, A. Sacher, P. Bradbury, F. Shepherd, N. Leighl, A. Pierre, P. Selby, D. Goldstein, W. Xu, M. Giuliani, W. Evans, G. Liu, M. Chaiton
Journal: Journal of Thoracic Oncology (2019)
EP1.12-37 Higher Consistency of Mutations Between Tumor DNA and ctDNA in Small-Cell Lung Cancer Compared to Non-Small Cell Lung Cancer
Authors: H. Ma, C. Li, J. Ma, H. Wang, F. Lou, S. Cao, Y. Zhu, L. Tong, Q. Zhang, X. Wang, T. Wang, W. Chang
Journal: Journal of Thoracic Oncology (2019)
EP1.04-15 NSCLC Response Determinants to Chemoimmunotherapy: Deep Profiling of Tumors Following Neoadjuvant Cemiplimab and Chemotherapy
Authors: T. Marron, A. Wolf, R. Flores, R. Veluswamy, J. Gomez, M.B. Beasley, D. Yankelevitz, A. Leader, I. Lowy, E. Miller, G. Thurston, V. Jankovic, R. Deering, B. Brown, A. Rahman, S. Gnjatic, F.R. Hirsch, N. Bhardwaj, M. Merad
Journal: Journal of Thoracic Oncology (2019)
Private Rights and the Public Interest in Drug and Medical Device Litigation
Authors: I. Glenn Cohen, Nicholas Bagley
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer
Authors: Douglas G. McNeel, Jens C. Eickhoff, Laura E. Johnson, Alison R. Roth, Timothy G. Perk, Lawrence Fong, Emmanuel S. Antonarakis, Ellen Wargowski, Robert Jeraj, Glenn Liu
Journal: Journal of Clinical Oncology (2019)

We previously reported the safety and immunologic effects of a DNA vaccine (pTVG-HP [MVI-816]) encoding prostatic acid phosphatase (PAP) in patients with recurrent, nonmetastatic prostate cancer. The current trial evaluated the effects of this vaccine on metastatic progression.Ninety-nine patients with castration-sensitive prostate cancer and prostate-specific antigen (PSA) doubling time (DT) of less than 12 months were randomly assigned to treatment with either pTVG-HP co-administered intradermally with 200 μg granulocyte-macrophage colony-stimulating factor (GM-CSF) adjuvant or 200 μg GM-CSF alone six times at 14-day intervals and then quarterly for 2 years. The primary end point was 2-year metastasis-free survival (MFS). Secondary and exploratory end points were median MFS, changes in PSA DT, immunologic effects, and changes in quantitative 18F-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT) imaging.Two-year MFS was not different between study arms (41.8% vaccine v 42.3%; P = .97). Changes in PSA DT and median MFS were not different between study arms (18.9 v 18.3 months; hazard ratio [HR], 1.6; P = .13). Preplanned subset analysis identified longer MFS in vaccine-treated patients with rapid (< 3 months) pretreatment PSA DT (12.0 v 6.1 months; n = 21; HR, 4.4; P = .03). PAP-specific T cells were detected in both cohorts, including multifunctional PAP-specific T-helper 1-biased T cells. Changes in total activity (total standardized uptake value) on 18F-NaF PET/CT from months 3 to 6 increased 50% in patients treated with GM-CSF alone and decreased 23% in patients treated with pTVG-HP (n = 31; P = .07).pTVG-HP treatment did not demonstrate an overall increase in 2-year MFS in patients with castration-sensitive prostate cancer, with the possible exception of a subgroup with rapidly progressive disease. Prespecified 18F-NaF PET/CT imaging conducted in a subset of patients suggests that vaccination had detectable effects on micrometastatic bone disease. Additional trials using pTVG-HP in combination with PD-1 blockade are under way.
P1.14-36 Phase II Trial of Afatinib in Elderly Patients Aged Over 75 Years with EGFR Mutation Positive Non-Small Cell Lung Cancer
Authors: R. Ko, S. Oizumi, H. Mizugaki, Y. Fujita, T. Harada, T. Takashina, S. Igawa, K. Watanabe, T. Hotta, H. Minemura, S. Saeki, S. Yagishita, A. Hamada
Journal: Journal of Thoracic Oncology (2019)
P1.12-09 RNA Sequencing in Small Cell Lung Carcinoma Reveals Change in Neuroendocrine Pattern in Primary Tumor Versus Lymph Node Metastases
Authors: Z. Lohinai, Z. Megyesfalvi, K. Suda, T. Harkó, R. Shengxiang, J. Moldvay, C. Rivard, B. Döme, F.R. Hirsch
Journal: Journal of Thoracic Oncology (2019)
P1.04-66 The Percentage of PD-L1 Besides 50% Positivity Predicts Objective Response to Pembrolizumab in Non-Small Cell Lung Cancer
Authors: A. Poma, G. Pasquini, R. Bruno, G. Alì, A. Proietti, I. Pecora, L. Petrini, E. Vasile, A. Chella, G. Fontanini
Journal: Journal of Thoracic Oncology (2019)
OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer
Authors: L. Bazhenova, M. Redman, S. Gettinger, F.R. Hirsch, P. Mack, L. Schwartz, D. Gandara, J. Bradley, T. Stinchcombe, N. Leighl, S. Ramalingam, S. Tavernier, K. Minichiello, K. Kelly, V. Papadimitrakopoulou, R. Herbst
Journal: Journal of Thoracic Oncology (2019)
Obstructive sleep apnoea severity and liver steatosis measured by magnetic resonance imaging
Authors: Wojciech Trzepizur, Jérôme Boursier, Anna Berréhare, Marc Le Vaillant, Ramaroson Andriantsitohaina, Pierre-Henri Ducluzeau, Séverine Dubois, Samir Henni, Pierre Abraham, Paul Calès, Christophe Aubé, Anita Paisant, Frédéric Gagnadoux
Journal: European Respiratory Journal (2019)

<b>In patients with OSA and metabolic comorbidities, liver steatosis measured by magnetic resonance imaging is associated with male sex and insulin resistance, but not with OSA severity and nocturnal hypoxia</b>http://bit.ly/2kqyi3O
Babylon: GPs’ concerns are being “resolved,” says Hancock
Authors: Abi Rimmer
Journal: BMJ (2019)

The health and social care secretary for England has told GPs that he is a patient of Babylon Healthcare, the company behind the controversial GP at Hand app.

Speaking to the Royal College of General Practitioners’ annual conference in Liverpool on 24 October by video stream from Westminster, Matt Hancock discussed GPs’ concerns about the app in regards to the effect it would have on patient lists and the work he was doing to resolve that. Concerns were raised earlier this year that the app would have a financial impact on other general practices by being less likely to take on patients with complex illness.1

“This whole …
Centralized Laboratory Testing for Inhibitors in the U.S. Hemophilia Treatment Centers Network: Testing Protocol and Results on 10,178 Specimens
Authors: Connie H Miller, Dorothy Ellingsen, Jennifer Driggers, Brian Boylan, Amanda B. Payne, Fiona Bethea, Vanessa R Byams, J. Michael Soucie, Christopher J. Bean
Journal: Blood (2017)
Clonal Interference of Signaling Mutations Holds Prognostic Relevance in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
Authors: Raphael Itzykson, Nicolas Duployez, Annette Fasan, Alice Marceau-Renaut, Manja Meggendorfer, Eric Jourdan, Arnaud Petit, Hélène Lapillonne, Jean-Baptiste Micol, Pascale Cornillet-Lefebvre, Norbert Ifrah, Guy Leverger, Herve Dombret, Nicolas Boissel, Torsten Haferlach, Claude Preudhomme
Journal: Blood (2017)
P1.04-60 Impact of Metastatic Location on Survival in Stage-IV Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy
Authors: A.R. Naqash, S. Jonnalagadda, S. Macherla, S. Polsani, M. Muzaffar, C. Cherry, N. Abdel Karim, P. Walker
Journal: Journal of Thoracic Oncology (2019)
The Low-Dimensional Neural Architecture of Cognitive Complexity Is Related to Activity in Medial Thalamic Nuclei
Authors: James M. Shine, Luke J. Hearne, Michael Breakspear, Kai Hwang, Eli J. Müller, Olaf Sporns, Russell A. Poldrack, Jason B. Mattingley, Luca Cocchi
Journal: Neuron (2019)
P1.14-43 A Novel Patient Derived Synchronous Cell Pair with Different Mutations in an ALK-Rearranged Lung Adenocarcinoma Underlines Tumor Heterogeneity
Authors: P. Stockhammer, C.S.L. Ho, A. Bankfalvi, T. Plönes, L. Hegedus, M. Schuler, C. Aigner, A. Schramm, B. Hegedus
Journal: Journal of Thoracic Oncology (2019)
EP1.03-13 Molecular Characteristics of East Asian Patients with VHL-Mutated Non-Small-Cell Lung Cancer: A Retrospective Study
Authors: J. Li, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Z. Huang, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2019)
Th17 Cells Targeting By MiR-21 Inhibitor Impairs Multiple Myeloma Related Bone Disease
Authors: Marco Rossi, Emanuela Altomare, Nicola Amodio, Maria Teresa Di Martino, Marco Gaspari, Domenico Taverna, Domenica Scumaci, Francesco Conforti, Daniele Caracciolo, Cirino Botta, Cinzia Federico, Annamaria Gullà, Eugenio Morelli, Francesca Scionti, Mariamena Arbitrio, Paola Critelli, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone
Journal: Blood (2017)
Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16
Authors: Sima Jeha, Deqing Pei, John Choi, Cheng Cheng, John T. Sandlund, Elaine Coustan-Smith, Dario Campana, Hiroto Inaba, Jeffrey E. Rubnitz, Raul C. Ribeiro, Tanja A. Gruber, Susana C. Raimondi, Raja B. Khan, Jun J. Yang, Charles G. Mullighan, James R. Downing, William E. Evans, Mary V. Relling, Ching-Hon Pui
Journal: Journal of Clinical Oncology (2019)

Despite contemporary treatment, up to 10% of children with acute lymphoblastic leukemia still experience relapse. We evaluated whether a higher dosage of PEG-asparaginase and early intensification of triple intrathecal therapy would improve systemic and CNS control.
P2.08-03 Clinical Outcome of Patients with Recurrent Non-Small Cell Lung Cancer After Trimodality Therapy
Authors: K. Suzawa, K. Araki, K. Nakata, S. Miyauchi, A. Miura, K. Namba, S. Otani, H. Yamamoto, M. Okazaki, S. Toyooka
Journal: Journal of Thoracic Oncology (2019)
P1.04-01 Body Mass Index and Age Do Not Influence Survival in Patients with Lung Cancers Treated with PD1/PDL1 Immune Checkpoint Inhibitors
Authors: C. Richard, A. Elkrief, J. Malo, L. Cvetkovic, M. Florescu, N. Blais, M. Tehfe, A. Gagné, C. Labbe, M. Orain, P. Joubert, F. Ghiringhelli, B. Routy
Journal: Journal of Thoracic Oncology (2019)
JCSE01.09 A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer
Authors: Y. Wu, C. Huang, Y. Fan, J. Feng, H. Pan, L. Jiang, J. Yang, X. Li, X. Liu, J. Xiong, Y. Zhao, Y. Cheng, R. Ma, J. Wang, Y. Wang, Y. Liu, D. Lin, W. Shi, X. Lin
Journal: Journal of Thoracic Oncology (2019)
MA11.02 KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
Authors: Y. Wu, L. Zhang, Y. Fan, J. Zhou, L. Zhang, Q. Zhou, W. Li, C. Hu, G. Chen, X. Zhang, C. Zhou, T. Dang, J. Penrod, D. Kush, Y. Qin, B. Li, T. Mok
Journal: Journal of Thoracic Oncology (2019)
A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises
Authors: Spencer Phillips Hey, Bishal Gyawali, Elvira D’Andrea, Manoj Kanagaraj, Jessica M Franklin, Aaron S Kesselheim
Journal: JNCI Journal of the National Cancer Institute (2019)

The US Food and Drug Administration's accelerated approval and later withdrawal of bevacizumab in patients with metastatic breast cancer (mBC) is a seminal case for ongoing debates about the validity of using progression-free survival (PFS) as a surrogate measure for overall survival (OS) in cancer drug approvals. We systematically reviewed and meta-analyzed the evidence around bevacizumab's regulatory approval and withdrawal in mBC.We searched for all published phase II or III clinical trials testing bevacizumab as a first-line therapy for patients with mBC. Data were extracted on trial demographics, interventions, and outcomes. Descriptive analysis was stratified by whether the trial was initiated before, during, or after the accelerated approval. We used a cumulative random-effects meta-analysis to assess the evolution of evidence of the effect of bevacizumab on PFS and OS. We estimated the association between the trial-level PFS and OS effect using a nonlinear mixed-regression model.Fifty-two studies were included. Trial activity dramatically dropped after the accelerated approval was withdrawn. Eight clinical trials reported hazard ratios (hazard ratios) and were meta-analyzed. The cumulative hazard ratio for PFS was 0.72 (95% CI = 0.65 to 0.79), and the cumulative hazard ratio for OS was 0.90 (95% CI = 0.80 to 1.01). The regression model showed a statistically nonsignificant association between PFS benefit and OS benefit (β = 0.43, SE = 0.81).The US Food and Drug Administration's decision-making in this case was consistent with the evolving state of evidence. However, the fact that seven clinical trials are insufficient to conclude validity (or lack thereof) for a trial-level surrogate suggests that it would be more efficient to conduct trials using the more clinically meaningful endpoints.
P1.03-25 Synergistic Lethality of Ferroptosis Inducer-Disulfiram/Copper Complex and WEE1 Kinase Inhibitor for RAS/TP53 Mutant NSCLC
Authors: B. Su, D. Liu, W. Xu, G. Lin, M. Zhao, N. Wang
Journal: Journal of Thoracic Oncology (2019)
P1.03-28 Prognostic Value of Estrogen Receptor Beta Tumor Expression in Non-Small Cell Lung Cancer Patients After Radical Surgery
Authors: A. Basharina, T. Bogush, E. Bogush, A. Grishanina, O. Ryabinina, N. Vichlzantseva, S. Kolomiytsev, B. Polotsky
Journal: Journal of Thoracic Oncology (2019)
MA01.09 Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study
Authors: P. Peng, Y. Chen, G. Han, R. Meng, S. Zhang, Z. Liao, Y. Zhang, J. Gong, C. Xiao, X. Liu, P. Zhang, L. Zhang, S. Xia, Q. Chu, Y. Chen, L. Zhang
Journal: Journal of Thoracic Oncology (2019)
P2.11-43 Management of Pulmonary Nodules Detected on CT: Multicenter Collaborative Study in Nagasaki Prefecture
Authors: S. Tsutsui, Y. Ogihara, H. Hayashi, K. Fukushima, S. Yoshida, M. Mori, H. Takatani, T. Fukuda, K. Minami, A. Fukushima, K. Morimoto, K. Kuroda, T. Nagayasu, H. Yamaguchi, H. Mukae, M. Fukuda, K. Ashizawa
Journal: Journal of Thoracic Oncology (2019)
MA03.07 First-Line Atezolizumab Chemoimmunotherapy in Advanced Non-Squamous NSCLC Patients Harboring EGFR/ALK Genetic Alterations
Authors: K. Thein, N. Jahan, A. Tun, A. Sultan, S. Swarup, F. Mogollon-Duffo, R. Yendala, M. Quirch, T. Htut, N. D’Cunha, S. Rehman, F. Hardwicke, S. Awasthi, L. Tijani
Journal: Journal of Thoracic Oncology (2019)
MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer
Authors: D.R. Camidge, F. Barlesi, J. Goldman, D. Morgensztern, R. Heist, E. Vokes, A. Spira, E. Angevin, W. Su, D. Hong, J. Strickler, M. Motwani, Z. Sun, A. Parikh, P. Komarnitsky, J. Wu, K. Kelly
Journal: Journal of Thoracic Oncology (2019)
EP1.01-13 A Phase 2 Trial Assessing Osimertinib Activity Against Leptomeningeal Carcinomatosis in EGFR-Mutant Lung Cancer
Authors: Y. Akazawa, S. Nanjo, M. Tamiya, A. Hata, T. Yamaguchi, T. Kumagai, M. Mori, N. Katakami
Journal: Journal of Thoracic Oncology (2019)
P2.03-06 Detection of ctDNA and Correlation with Tumor Mutation Testing in Early Stage NSCLC
Authors: A. Dimou, T. Patil, A. Jeffers, A. Guimaraes-Young, K. Davies, T. Nance, Y. He, A. Jaimovich, V. Raymond, A. Talasaz, E. Schenk, J. Pacheco, D. Aisner, D. Merrick, C. Scott, J. Mitchell, M. Weyant, R. Meguid, W.T. Purcell, P. Bunn, D.R. Camidge, T. Ng, C. Mccoach, R. Doebele
Journal: Journal of Thoracic Oncology (2019)
P2.11-07 Benefits and Harms of Contemporary Lung Cancer Screening: An Infographic to Support Public and Patient Education
Authors: H. Robbins, M. Callister, P. Sasieni, S. Quaife, L. Cheung, P. Brennan, H. Katki, C. Berg, D. Baldwin, M. Johansson
Journal: Journal of Thoracic Oncology (2019)